About Event
Why Should You Prioritize the IPF Summit?
In a year marked by notable clinical setbacks, the industry was buoyed by the promise of ongoing phase 2 and phase 3 trials, igniting a sense of hope and excitement throughout the field.
With new research consistently emerging, technologies being refined and breakthroughs at our fingertips, the ever-present industry challenges remain. With that, lies a unique opportunity to confront these hurdles head-on, drawing invaluable lessons from the clinical failures of the past and leveraging them to fortify and refine our current therapeutic development efforts.
For the past 8 years, the IPF Summit has consistently provided a vital forum for dedicated pulmonary fibrosis professionals to share knowledge, uncover creative solutions and work together to tackle those ever-present challenges from effective preclinical models to endpoints truly reflective of progress and even innovative clinical trial design, and the 9th IPF Summit will return in 2025 to do exactly that.
What You Missed at the 8th IPF Summit:
Who Would You Have Met?
150+ decision makers representing the leading pulmonary fibrosis biopharma companies gathered together along with the industry’s foremost thought leaders including Toby Maher, Fernando Martinez and Eric White, to name a few.
This inclusive gathering united individuals from across the drug development cycle including discovery, preclinical research, translational, biomarker, clinical, regulatory, and patient recruitment, all united in a collective effort to propel innovative and efficacious pulmonary fibrosis therapeutics through Phase 2 and phase 3 to patients in need.
